Publicacións (38) Publicacións nas que participase algún/ha investigador/a

2009

  1. A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma

    Cancer Chemotherapy and Pharmacology, Vol. 64, Núm. 2, pp. 379-384

  2. Akt activation synergizes with Trp53 loss in oral epithelium to produce a novel mouse model for head and neck squamous cell carcinoma

    Cancer Research, Vol. 69, Núm. 3, pp. 1099-1108

  3. Brain metastases from prostate adenocarcinoma

    Clinical and Translational Oncology, Vol. 11, Núm. 1, pp. 63-64

  4. Clinical-molecular factors predicting response and survival for tyrosine-kinase inhibitors

    Clinical and Translational Oncology, Vol. 11, Núm. 7, pp. 428-436

  5. Clonality of mouse and human cardiomyogenesis in vivo

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 106, Núm. 40, pp. 17169-17174

  6. Combination therapy with docetaxel and low dose of cisplatin in elderly patients with advanced non-small cell lung cancer: Multicenter phase II study

    Cancer Chemotherapy and Pharmacology, Vol. 63, Núm. 3, pp. 403-409

  7. Comprehensive lung injury pathology induced by mTOR inhibitors

    Clinical and Translational Oncology, Vol. 11, Núm. 8, pp. 499-510

  8. Diagnostic accuracy of small breast epithelial mucin mRNA as a marker for bone marrow micrometastasis in breast cancer: A pilot study

    Journal of Cancer Research and Clinical Oncology, Vol. 135, Núm. 9, pp. 1185-1195

  9. Expression of Wnt gene family and frizzled receptors in head and neck squamous cell carcinomas

    Virchows Archiv, Vol. 455, Núm. 1, pp. 67-75

  10. HLA-B27 polymorphism at position 116 critically influences the association with TAP/tapasin, intracellular trafficking and conformational homodimers formation

    Molecular Immunology, Vol. 46, Núm. 7, pp. 1304-1311

  11. High levels of tumor markers in pleural fluid correlate with poor survival in patients with adenocarcinomatous or squamous malignant effusions

    European Journal of Internal Medicine, Vol. 20, Núm. 4, pp. 383-386

  12. KIR genes and their role in spondyloarthropathies

    Advances in Experimental Medicine and Biology, Vol. 649, pp. 286-299

  13. La ciclooxigenasa-2 (COX-2) y el factor de crecimiento epidérmico (EFG) en lesiones epiteliales orales premalignas

    Revista Espanola de Cirugia Oral y Maxilofacial, Vol. 31, Núm. 3, pp. 170-181

  14. La expresión inmunohistoquímica intensa de ciclooxigenasa 2 se asocia inversamente con los valores máximos de SUV en la 18F-FDG-PET de pacientes afectados de carcinomas no microcíticos de pulmón. Relación con otros factores biológicos

    Revista española de medicina nuclear, Vol. 28, Núm. 1, pp. 11-14

  15. Masas abdominales pulsátiles

    Revista Clinica Espanola, Vol. 209, Núm. 5, pp. 247-249

  16. Metástasis única en próstata de carcinoma microcítico pulmonar

    Archivos Espanoles de Urologia, Vol. 62, Núm. 2, pp. 141-144

  17. Molecular analysis of the APC and MUTYH genes in Galician and Catalonian FAP families: A different spectrum of mutations?

    BMC Medical Genetics, Vol. 10

  18. Nitrofurantoína y enfermedad pulmonar intersticial de rápida resolución

    Archivos de Bronconeumologia, Vol. 45, Núm. 7, pp. 352-355

  19. Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial

    Breast Cancer Research and Treatment, Vol. 116, Núm. 2, pp. 351-358

  20. Non-small cell lung cancer management based on EGFR mutation status

    American Journal of Hematology/ Oncology, Vol. 8, Núm. 12